diaDexus, Inc. announced the appointment of Pat Arensdorf as general manager and head of the heart failure business unit with responsibility for the development and commercialization of the company's heart failure biomarkers. Most recently, he was chief executive officer of Critical Diagnostics, where he led a new regulatory strategy resulting in the most recent FDA clearance of a novel heart failure biomarker.